PharmaNews.eu

Innovative public-private collaboration launches to tackle antibiotic research

ruslan.david@gmail.com (Administrator) — Thu, 24 May 2012 22:00:00 +0000

AstraZeneca and GlaxoSmithKline welcomed the launch of a pioneering approach to antibiotic research in Europe that will see pharmaceutical and biotechnology companies working alongside public partners to tackle the rising threat from antibiotic resistance and address some of the key barriers to the development of effective antibiotics. The objective of the proposed research programme is to improve the underlying scientific understanding of antibiotic resistance, design and implement efficient clinical trials and take novel drug candidates through clinical development.

IMI launches €223.7 million programme for combatting antibiotic resistance

ruslan.david@gmail.com (Administrator) — Thu, 24 May 2012 08:00:00 +0000

Today the Innovative Medicines Initiative (IMI) is launching a €223.7 million programme which will see leading academics and five major pharmaceutical companies join forces to tackle antimicrobial resistance and to speed up the delivery of much-needed new antibiotics to patients. Antibiotic resistance poses a major health threat to society and despite the recognised need for new antibiotics, the reality is that only two new classes of antibiotics have been brought to market in the last 30 years.

One million signatures needed to call upon World Health Organisation

ruslan.david@gmail.com (Administrator) — Tue, 22 May 2012 22:00:00 +0000

The 1 Mission 1 Million - Getting to the Heart of Stroke initiative is launching a petition to call upon the World Health Organisation, its member states and health authorities worldwide to recognise atrial fibrillation as a risk factor for stroke and set clinical management targets that could save one million mothers, fathers, uncles, aunts and grandparents each year through better atrial fibrillation management, stroke prevention and education.

Biomarker predicts response to cancer treatment

ruslan.david@gmail.com (Administrator) — Mon, 21 May 2012 22:00:00 +0000

VIB researcher Diether Lambrechts, associated with KU Leuven, has discovered a biomarker that might potentially predict which patients will benefit more from treatment with bevacizumab (Avastin). If validated, this discovery could be an important step towards personalized medicine and patient-tailored use of this important cancer drug.

Heparin-like compounds inhibit breast cancer metastasis to bone

ruslan.david@gmail.com (Administrator) — Sun, 20 May 2012 22:00:00 +0000

Researchers from VTT Technical Research Centre of Finland have in collaboration with the University of Turku, Indiana University and two Finnish companies, Biotie Therapies Corp. and Pharmatest Services Ltd, discovered a novel mechanism regulating the development of breast cancer bone metastases and showed that heparin-like compounds can potentially be used to inhibit breast cancer metastasis to bone. These findings were published on the Molecular Cancer Research journal website on 20th April 2012.

Health 2.0 Europe 2012 - Over 20 speakers already confirmed

ruslan.david@gmail.com (Administrator) — Wed, 16 May 2012 22:00:00 +0000

6 - 7 November 2012, Berlin, Germany.
What is Health 2.0 Europe about? It's about a new generation of entrepreneurs believing they can be the change they want to see in their health systems. It's about engaging a deeper conversation and widening our perspective on today's health eco-system: it's not just about social media and communities, it's also about patient-physician communication, system reform, data, analytics, population health management, personalized medicine, sensors/devices/unplatforms, wellness... The conference is about leveraging the international Health 2.0 community to promote cross-pollination of ideas and technology collaboration. It's about start-ups leading the way into the future of healthcare.

Merck total revenues increase 3.2% to € 2.6 billion

ruslan.david@gmail.com (Administrator) — Tue, 15 May 2012 22:00:00 +0000

The Merck Group's first-quarter 2012 total revenues rose 3.2% to € 2,645 million compared to € 2,564 million in the first quarter of 2011. Sales for the Group increased 3.5% to € 2,564 million in first quarter compared to € 2,478 million in the year-ago quarter. This performance reflected organic sales growth of 1.2%, a 1.7% positive benefit from changes in foreign exchange rates and a 0.6% boost from acquisitions and divestments. The Group’s organic sales growth was entirely driven by the Merck Serono and Merck Millipore divisions during the quarter.

Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe

ruslan.david@gmail.com (Administrator) — Tue, 15 May 2012 12:00:00 +0000

Abbott (NYSE: ABT) today announced that the XIENCE PRIME™ and the XIENCE V® Everolimus Eluting Coronary Stent Systems have received CE Mark in Europe for the use of dual anti-platelet therapy (DAPT) for at least three months after stent implantation in patients with coronary artery disease. This is the shortest duration of DAPT for any major drug eluting stent (DES) in Europe.

GSK statement on BBC Panorama broadcast: 'the truth about tax'

ruslan.david@gmail.com (Administrator) — Mon, 14 May 2012 12:00:00 +0000

GSK issued the following statement in response to the BBC Panorama programme related to Corporation Tax payments in the UK and Luxembourg broadcast tonight, Monday 14 May 2012. "GSK is very disappointed with this programme which was extremely misleading and lacking in context. Specifically, the programme's selective use of facts led to a misrepresentation of GSK's actions and a failure to recognize GSK's significant UK tax contribution.

Finnish researchers discover genes inhibiting the spread of prostate cancer

ruslan.david@gmail.com (Administrator) — Fri, 11 May 2012 10:00:00 +0000

The research team of Professor Johanna Ivaska (University of Turku and VTT Technical Research Centre of Finland) screened dozens of prostate cancers using gene silencing and discovered mechanisms of that inhibit the spread of cancer cells. Published in the Journal of Cell Science, the study shows that cancer cell adhesive activity, which is easy to measure in a laboratory setting, is directly linked to the ability of the cancer cells to metastasise. As a result, screening for regulators of cancer cell activity can lead to the discovery of new candidates for pharmaceutical development.